Twist Bioscience Corp
For the period ended Sep 30, 2024. Filed Nov 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 18, 2024
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year ended September 30, | |||
|---|---|---|---|
| (In thousands, except per share data) | 2024 | 2023 | 2022 |
| Revenues [1] | $312,974 | $245,109 | $203,565 |
| Operating expenses: | |||
| Cost of revenues | $179,625 | $155,380 | $119,330 |
| Research and development | 90,852 | 106,894 | 120,307 |
| Selling, general and administrative | 218,398 | 189,738 | 212,949 |
| Restructuring and other costs | — | 9,384 | — |
| Change in fair value of contingent considerations and holdbacks | — | (5,913) | (14,245) |
| Impairment of long-lived assets | 44,930 | 6,785 | — |
| Total operating expenses | $533,805 | $462,268 | $438,341 |
| Loss from operations | $(220,831) | $(217,159) | $(234,776) |
| Interest income | 15,344 | 14,365 | 3,062 |
| Interest expense | (29) | (5) | (80) |
| Gain on deconsolidation of subsidiary | — | — | 4,607 |
| Other income (expense), net | (2,650) | (667) | (1,087) |
| Loss before income taxes | $(208,166) | $(203,466) | $(228,274) |
| Income tax (expense) benefit | (560) | (1,152) | 10,411 |
| Net loss attributable to common stockholders | $(208,726) | $(204,618) | $(217,863) |
| Other comprehensive income (loss): | |||
| Change in unrealized gain (loss) on investments | $203 | $1,510 | $(1,594) |
| Foreign currency translation adjustment | 31 | (423) | (795) |
| Comprehensive loss | $(208,492) | $(203,531) | $(220,252) |
| Net loss per share attributable to common stockholders—basic and diluted | $(3.60) | $(3.60) | $(4.04) |
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 58,016 | 56,885 | 53,885 |
[1]During the years ended September 30, 2024, 2023 and 2022, the Company had revenues from related parties in the amount of $12.1 million, $5.9 million and $3.5 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.